Brief: Rigel Pharmaceuticals Q3 EPS USD 0.71 Vs. IBES Estimate USD 0.06
07/11/2024 21:01
Nov 07 (Reuters) - Rigel Pharmaceuticals Q3 revenue USD 55.3 million vs. IBES estimate USD 41.9 million. * Q3 net income USD 12.4 million vs. IBES estimate USD 910.2 thousand
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)